Pharmacogenomic-Guided Medication Management for Depression
(COMPASS-PGx Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this prospective, randomized clinical trial is to learn whether pharmacogenomic (PGx)-guided comprehensive medication management delivered by pharmacists in community pharmacies will improve antidepressant treatment outcomes.
The primary aim is to determine whether comprehensive medication management with review of PGx testing results improves depression symptoms, compared with usual care.
Participants 18 years of age or older who have undergone PGx testing (e.g. through an independent biobanking study (Pitt+Me Discovery) who require initiation or adjustment of antidepressant therapy will be randomly assigned to receive either PGx-guided comprehensive medication management or usual care. Those who receive usual care will receive their PGx results at the end of the study. Researchers will compare the groups to assess whether PGx-guided care provided in partnership with community pharmacists and prescribers results in better depression and medication outcomes.
Who Is on the Research Team?
Philip E Empey, PharmD, PhD
Principal Investigator
University of Pittsburgh
Are You a Good Fit for This Trial?
This trial is for adults over 18 with depression who are starting or changing doses of certain antidepressants (SSRIs or SNRIs/bupropion). They must have mild depressive symptoms confirmed by a PHQ8 assessment, speak English, and be part of the Pitt+Me Discovery biobanking study. Participants need to be UPMC patients or willing to become one.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive PGx-guided comprehensive medication management or usual care
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Comprehensive Medication Management with Pharmacogenomic Results
Trial Overview
The trial is testing if pharmacist-led medication management using pharmacogenomic (PGx) test results can improve depression treatment outcomes compared to usual care without PGx guidance. Patients will either receive personalized medication adjustments based on their genetic profile or standard treatment.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Participants will receive no study intervention (usual care) and will have a comprehensive medication management with review of PGx testing results at the end of the study.
Participants will have a study visit with a community pharmacist for comprehensive medication management with review of PGx testing results.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pittsburgh
Lead Sponsor
Pennsylvania Department of Health
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.